Gangemi Sebastiano, Basile Giorgio, Merendino Rosaria Alba, Epifanio Antonio, Di Pasquale Giuseppe, Ferlazzo Benito, Nicita-Mauro Vittorio, Morgante Letterio
School and Division of Allergy and Clinical Immunology, Via Centonze n. 200 is. 98, 98123 Messina, Italy.
Mediators Inflamm. 2003 Aug;12(4):251-3. doi: 10.1080/09629350310001599701.
Parkinson's disease (PD) is an extra-pyramidal neurodegenerative disorder, in which alterations of the immune system are involved. Interleukin (IL)-15 stimulates cellular immune response and induces growth and differentiation of various immune cells. RANTES, promoting leukocyte infiltration to sites of inflammation, mediates the trafficking and homing of immune cells. To clarify the potential effect of levodopa on the immunological network of PD, we analyzed IL-15 and RANTES serum levels in PD patients, treated or not with levodopa, and in healthy donors. Levodopa-treated patients showed significantly higher IL-15 and RANTES circulating levels with respect to healthy controls and higher, although not significantly, levels with respect to untreated patients. So, we hypothesize that the immunological alterations found in PD may be linked, at least in part, to levodopa therapy.
帕金森病（PD）是一种锥体外系神经退行性疾病，免疫系统的改变也参与其中。白细胞介素（IL）-15刺激细胞免疫反应，并诱导各种免疫细胞的生长和分化。调节活化正常T细胞表达和分泌因子（RANTES）促进白细胞向炎症部位浸润，介导免疫细胞的运输和归巢。为了阐明左旋多巴对帕金森病免疫网络的潜在影响，我们分析了接受或未接受左旋多巴治疗的帕金森病患者以及健康供体血清中IL-15和RANTES的水平。与健康对照组相比，接受左旋多巴治疗的患者循环中IL-15和RANTES水平显著更高，与未治疗患者相比，水平也更高，尽管差异不显著。因此，我们推测帕金森病中发现的免疫改变可能至少部分与左旋多巴治疗有关。
